Zai Lab (HKSE:09688) Total Liabilities : HK$2,681 Mil (As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Zai Lab Total Liabilities?

Zai Lab's Total Liabilities for the quarter that ended in Dec. 2024 was HK$2,681 Mil.

Zai Lab's quarterly Total Liabilities increased from Jun. 2024 (HK$2,211.71 Mil) to Sep. 2024 (HK$2,475.02 Mil) and increased from Sep. 2024 (HK$2,475.02 Mil) to Dec. 2024 (HK$2,680.70 Mil).

Zai Lab's annual Total Liabilities increased from Dec. 2022 (HK$1,358.90 Mil) to Dec. 2023 (HK$1,875.73 Mil) and increased from Dec. 2023 (HK$1,875.73 Mil) to Dec. 2024 (HK$2,680.70 Mil).

Zai Lab Total Liabilities Historical Data

The historical data trend for Zai Lab's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zai Lab Total Liabilities Chart

Zai Lab Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Liabilities

Get a 7-Day Free Trial

994.52

1,793.77

1,358.90

1,875.73

2,680.70

Zai Lab Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Liabilities	Get a 7-Day Free Trial															1,875.73	1,770.10	2,211.71	2,475.02	2,680.70

Zai Lab Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Zai Lab's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	2327.239	+	(106.589	+	2.5269999999999
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	244.341	+	0)
	=	2,681

Total Liabilities	=	Total Assets (A: Dec. 2024 )	-	Total Equity (A: Dec. 2024 )
	=	9217.332	-	6536.637
	=	2,681

Zai Lab's Total Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	2327.239	+	(106.589	+	2.5269999999999
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	244.341	+	0)
	=	2,681

Total Liabilities	=	Total Assets (Q: Dec. 2024 )	-	Total Equity (Q: Dec. 2024 )
	=	9217.332	-	6536.637
	=	2,681

Zai Lab Total Liabilities Related Terms

Thank you for viewing the detailed overview of Zai Lab's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Zai Lab Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zai Lab Ltd (HKSE:09688) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

ZLAB:USA 1ZLB:Germany

Address

4560 Jinke Road, Jinchuang Plaza, Building 1, 4th Floor, Pudong, Shanghai, CHN, 201210

Website

https://www.zailaboratory.com

Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatments across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.

Executives

Janus Henderson Group Plc	2102 Investment manager
Wellington Management Group Llp	2102 Investment manager
Fmr Llc	2201 Interest of corporation controlled by you
Jpmorgan Chase & Co.	2201 Interest of corporation controlled by you
Du Ying	2101 Beneficial owner
The Capital Group Companies, Inc.	2201 Interest of corporation controlled by you
Ubs Group Ag	2201 Interest of corporation controlled by you
Qiming Corporate Gp Iv, Ltd.
Qiming Gp Iv, L.p.
Qiming Venture Partners Iv, L.p.
Qm11 Limited
Invesco Advisers, Inc.	2102 Investment manager
Invesco Developing Markets Fund	2106 Person having a security interest in shares
Baillie Gifford & Co	2102 Investment manager
Citigroup Inc.	2502 Approved lending agent

Zai Lab Headlines

No Headlines